|David W. Blank, M.D., CM FRCPC
david.blank [at] muhc.mcgill.ca
Studies related to the practice of clinical chemistry and clinical studies on patients with dyslipidemias.
As director of the Clinical Biochemistry Division, most of my time is directed towards running that Division and the Clinical Biochemistry Laboratory of the Hospital. From this perspective comes one focus of my current research: evaluating new tests for clinical use at the bench level and its clinical utility.Recently, these have included evaluation of different technologies for cyclosporin quantitation and cardiac markers. For many years, I have been interested in the dyslipidemias. Consequently, this group of patients has formed the basis of my clinical practice centered at the RVH Lipid Clinic. The Lipid Clinic has evolved into a large clinic in the Endocrine Division over the years. Clinical trials using this patient base have been done in collaboration with Dr. M. Sherman (Endocrinology).
Gilfix, B.M., Blank, D.W., Rosenblatt, D.S. The use of a novel reductant in the determination of total plasma homocysteine. Clin. Chem. 43: 687-688, 1997.